Lantheus acquires Meilleur to expand portfolio with PET imaging agent NAV-4694
Lantheus gets exclusive global rights to Meilleur’s beta-amyloid PET imaging agent, NAV-4694, which is currently in Phase 3 development and being used in investigational studies
![](https://www.medicaldevice-developments.com/wp-content/uploads/sites/11/2024/07/New-Project-50-1024x576.webp)
Societal polarisation and its impact on the medical device development industry
Addressing the challenges posed by extreme weather events in the medical device development industry
Economic downturn: challenges and opportunities in the medical device development industry
Biodiversity loss and ecosystem collapse: the impact on the medical device development industry